CWP
VRTX icon

Concord Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Concord Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5
Closed -$1.96K – 896
2025
Q3 		$1.96K Sell
5
-85
-94% -$35.5K ﹤0.01% 713
2025
Q2 		$40.1K Sell
90
-3,459
-97% -$1.59M 0.01% 374
2025
Q1 		$1.72M Buy
3,549
+41
+1% +$19.1K 0.28% 83
2024
Q4 		$1.41M Buy
3,508
+862
+33% +$400K 0.23% 87
2024
Q3 		$1.23M Buy
2,646
+349
+15% +$168K 0.21% 85
2024
Q2 		$1.08M Buy
2,297
+658
+40% +$286K 0.19% 96
2024
Q1 		$685K Buy
1,639
+483
+42% +$204K 0.12% 120
2023
Q4 		$470K Buy
1,156
+400
+53% +$148K 0.09% 134
2023
Q3 		$263K Buy
756
+128
+20% +$44.8K 0.06% 169
2023
Q2 		$221K Buy
628
+276
+78% +$93K 0.05% 187
2023
Q1 		$111K Buy
352
+332
+1,660% +$99.6K 0.03% 238
2022
Q4 		$5.78K Buy
+20
New +$6.09K ﹤0.01% 730
2022
Q3 		– Sell
-103
Closed -$29K – 1131
2022
Q2 		$29K Sell
103
-30
-23% -$8.03K 0.01% 462
2022
Q1 		$35K Buy
133
+14
+12% +$3.32K 0.01% 502
2021
Q4 		$26K Buy
119
+105
+750% +$20.4K 0.01% 591
2021
Q3 		$3K Sell
14
-30
-68% -$5.86K ﹤0.01% 715
2021
Q2 		$9K Sell
44
-4
-8% -$837 ﹤0.01% 644
2021
Q1 		$10K Buy
+48
New +$10.5K ﹤0.01% 587

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Concord Wealth Partners's VRTX Position: Q4 2025 in Review

Concord Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 5 shares — an estimated $1.96K sold.

Concord Wealth Partners first reported a position in VRTX in Q1 2021 and held it in 18 quarters. The position peaked at $1.72M in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Concord Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Concord Wealth Partners sold 5 Vertex Pharmaceuticals shares in Q4 2025, an estimated $1.96K.
  • Concord Wealth Partners first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 18 quarters.
  • Concord Wealth Partners's Vertex Pharmaceuticals position peaked at $1.72M in Q1 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Concord Wealth Partners's 13F filing for Q4 2025, filed 29 Jan 2026.